Nrx Pharmaceuticals Inc (NRXP) Stock Price, Quote & News

Company Profile

NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain. Its lead drug candidates include NRX-101, an oral, fixed dosed combination of D-cycloserine and lurasidone for suicidal treatment-resistant bipolar depression in patients with sub-acute suicidal ideation and behavior in phase 2 trial; and NRX-100, a preservative-f...

Industry: Biotechnology

Sector: Healthcare

Phone: 484 254 6134

Website: www.nrxpharma.com

Address:

1201 Orange Street, Suite 600, Wilmington, United States

Outcomes Feb. 25 at 11:21 AM

$NRXP

0 · Reply

the_franz Feb. 25 at 8:16 AM

$NRXP Stability data is one thing but you failed to address the missing NDA. We were told that NDA for NRX-100 is filed early 2024 and 2 years later you tell your shareholders you now *believe* to have "a path to filing an application for New Drug Approval of NRX-100". So you were never ready for early 2024? You misjudged the situation. That can happen, but you can communicate clearly, admit your misjudgment, and chalk it up as a learning experience. No one here knows why we didn't file in early 2024. No one knows why we still haven't filed after the first round of CNPV. Suddenly RWE is coming around the corner and serves as another excuse. Don't forget that parents are now pregnant for the second time since you started the NDA in December 2024, while your (unloved, I assume, because originally this company was about NRX-101) baby still hasn't been born. One has to assume that for some reason there is intentional delaying. To label this as FUD is an impertinence!

1 · Reply

JavittMD Feb. 24 at 10:35 PM

$NRXP @jonny80s All of you who keep worrying about NRX-100 preservative-free drug stability and throwing FUD, we keep reporting that we expect to launch with 3 years of ROOM TEMPERATURE stable shelf life. Anybody who is worried is welcome to visit our manufacturer and look at the data. Just call Brian and schedule a visit.

4 · Reply

BlazingStocks Feb. 24 at 8:34 PM

$NRXP - NRX-100 (preservative-free ketamine) has been granted Fast Track Designation by FDA for treatment of suicidal ideation in patients with Depression and Bipolar Depression. https://finance.yahoo.com/news/nrx-pharmaceuticals-nasdaq-nrxp-announces-120300036.html

0 · Reply

jonny80s Feb. 24 at 8:02 PM

$NRXP sometimes I wonder if Anson was selling call options all of 2025 knowing full well that none of Javitt’s “wishful thinking” projections had any chance in hell of materializing.

0 · Reply

IChiGOdoranZ Feb. 24 at 7:29 PM

$NRXP New to The Street and Wall Street New York Magazine Launch Weekly Executive Publication with Integrated NewsOut Video Press Distribution

0 · Reply

Stockprofiler Feb. 24 at 6:43 PM

$NRXP FDA Meeting Indicates Path to New Drug Application with Real World Data and Broader Indication of NRX-100 (Ketamine) for Suicidal Depression: NRx Pharmaceuticals, Inc. (Nasdaq: $NRXP) Read More - https://markets.financialcontent.com/bostonherald/article/getnews-2026-2-17-fda-meeting-indicates-path-to-new-drug-application-with-real-world-data-and-broader-indication-of-nrx-100-ketamine-for-suicidal-depression-nrx-pharmaceuticals-inc-nasdaq-nrxp/ #PharmaNews #mentalhealth #ketamine #NRXPharma $NRXP https://x.com/NRxPharma/status/2025972674187649291

0 · Reply

DonDon531 Feb. 24 at 5:13 PM

$NRXP looking good!!!

0 · Reply

fuctonfauci Feb. 24 at 4:31 PM

$NRXP How many years does the FDA take to provide written feedback for a Type C meeting with NRx?

2 · Reply

Stockfit1 Feb. 24 at 4:21 PM

@ItTakesItAll Did you add $NRXP back in January

0 · Reply

NRx Pharmaceuticals (Nasdaq:NRXP) Announces Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 (ketamine) Following Type C FDA Meeting

Jan 16, 2026, 7:03 AM EST - 5 weeks ago

NRx Pharmaceuticals (Nasdaq:NRXP) Announces 2025 Annual Meeting Date and Record Date

Jan 14, 2026, 7:03 AM EST - 5 weeks ago

NRx Pharmaceuticals (Nasdaq:NRXP) Announces 70,000 Patient Data on Real World Use of Ketamine for Treatment of Suicidal Depression to be Submitted to the FDA in Support of NRX-100 Approval

Jan 5, 2026, 6:57 AM EST - 7 weeks ago

NRx Pharmaceuticals (Nasdaq:NRXP) and neurocare Group AG Announce Joint Offering of Neuroplastic Therapy Targeting Depression, PTSD, and other mental health afflictions

Dec 18, 2025, 7:05 AM EST - 2 months ago

NRx Pharmaceuticals (Nasdaq:NRXP) announces elimination of all balance sheet debt following equity conversion

Dec 3, 2025, 7:00 AM EST - 2 months ago

NRx Pharmaceuticals to discuss new NRX-101 pipeline indication for augmentation of Transcranial Magnetic Stimulation

Dec 2, 2025, 11:23 AM EST - 3 months ago

NRx Pharmaceuticals, Inc. (NRXP) Discusses Regulatory Update and Development Pipeline Expansion for Preservative-Free Ketamine Formulation Transcript

Dec 2, 2025, 8:30 AM EST - 3 months ago

NRx Pharmaceuticals Announces US Food and Drug Administration (FDA) Receipt of ANDA for KETAFREE™, a Preservative-Free IV Ketamine

Dec 2, 2025, 7:30 AM EST - 3 months ago

NRx Pharmaceuticals (NASDAQ: NRXP) and HOPE Therapeutics to Host Corporate Update Call

Dec 1, 2025, 8:03 AM EST - 3 months ago

NRx Pharmaceuticals (NASDAQ:NRXP) and HOPE Therapeutics to Present at NobleCon21 - Noble Capital Markets' Twenty First Annual Emerging Growth Equity Conference

Nov 17, 2025, 11:57 AM EST - 3 months ago

NRx Pharmaceuticals, Inc. (NRXP) Q3 2025 Earnings Call Transcript

Nov 17, 2025, 8:03 AM EST - 3 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 12, 2025, 8:31 AM EST - 3 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Third Quarter 2025 Financial Results on November 17, 2025

Nov 10, 2025, 8:03 AM EST - 3 months ago

HOPE Therapeutics, Inc., an NRx Pharmaceuticals Subsidiary, Announces First-in-Florida Initiation of One Day (ONE-D) Depression Treatment in Partnership with Ampa Health

Oct 20, 2025, 8:03 AM EDT - 4 months ago

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Inclusion of Cohen & Associates, LLC of Sarasota, FL into the HOPE Network and Appointment of Dr. Rebecca Cohen as HOPE Medical Director

Oct 6, 2025, 8:03 AM EDT - 5 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Present at Noble Capital Markets October 2025 Emerging Growth Virtual Equity Conference

Sep 29, 2025, 8:03 AM EDT - 5 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Re-Files Abbreviated New Drug Application (ANDA) for KETAFREE™, Preservative-Free IV Ketamine

Sep 24, 2025, 8:03 AM EDT - 5 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Notification of US Food and Drug Administration Approval of Suitability Petition for NRx's Proposed Strength of Preservative-Free Ketamine

Sep 8, 2025, 8:17 AM EDT - 6 months ago

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Complete the Acquisition of Dura Medical; Initial Acquisition in Network of Interventional Psychiatry Clinics

Sep 3, 2025, 8:03 AM EDT - 6 months ago

NRx Pharmaceuticals (NASDAQ:NRXP) to Participate in a Fireside Chat at H.C. Wainwright's 27th Annual Global Investment Conference on Monday, September 8th

Sep 2, 2025, 1:19 PM EDT - 6 months ago

UPDATE -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Selected to Present at the 2025 Global Passion Project with Matthew Rockefeller, Sponsored by Rockefeller Global Family Office

Sep 2, 2025, 8:41 AM EDT - 6 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Selected to Present at the 2025 Global Passion Project with Matthew Rockefeller and Rockefeller Capital

Aug 27, 2025, 8:03 AM EDT - 6 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Expanded Access Policy for NRX-100 (preservative-free ketamine)

Aug 20, 2025, 12:23 PM EDT - 6 months ago

NRx Pharmaceuticals, Inc. (NRXP) Q2 2025 Earnings Call Transcript

Aug 18, 2025, 8:10 AM EDT - 6 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 13, 2025, 6:06 PM EDT - 6 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reschedules Second Quarter 2025 Financial Results Release to August 19, 2025

Aug 11, 2025, 4:05 PM EDT - 7 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Second Quarter 2025 Financial Results on August 14, 2025

Aug 11, 2025, 8:03 AM EDT - 7 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Granted FDA Fast Track Designation for NRX-100 for Suicidal Ideation in Patients with Depression, including Bipolar Depression

Aug 8, 2025, 8:03 AM EDT - 7 months ago

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Receipt of Final Clearance to Proceed to Closing of Dura Medical Acquisition from Florida's Agency for Health Care Administration (AHCA)

Aug 4, 2025, 8:03 AM EDT - 7 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Filing of a Citizen Petition with the US Food and Drug Administration Seeking Removal of Benzethonium Chloride from Ketamine Products

Jul 29, 2025, 8:03 AM EDT - 7 months ago

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Join Fireside Chat at BTIG Virtual Biotech Conference July 29 - 30, 2025

Jun 26, 2025, 8:03 AM EDT - 8 months ago

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Agreement to Acquire Interest in Cohen and Associates, LLC for HOPE's Network of Interventional Psychiatry Clinics

Jun 23, 2025, 8:03 AM EDT - 8 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Filing of Commissioner's National Priority Voucher Application for Intravenous Ketamine (NRX-100)

Jun 16, 2025, 8:03 AM EDT - 9 months ago

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) and HOPE Therapeutics, Inc. Announce Strategic Investor Relations Partnership with astr partners

Jun 12, 2025, 8:03 AM EDT - 9 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics, Inc. to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

Jun 5, 2025, 8:03 AM EDT - 9 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Files Abbreviated New Drug Application (ANDA) for Preservative-Free IV Ketamine

May 16, 2025, 8:46 PM EDT - 10 months ago

NRx Pharmaceuticals, Inc. (NRXP) Q1 2025 Earnings Call Transcript

May 15, 2025, 4:03 PM EDT - 10 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 15, 2025, 10:15 AM EDT - 10 months ago

HOPE Therapeutics, Inc. a subsidiary of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Signing of Term Sheet for $7.8 Million Debt Financing to Fuel HOPE Clinic Acquisitions

May 13, 2025, 8:03 AM EDT - 10 months ago

HOPE Therapeutics, Inc. and NRx Pharmaceuticals (NASDAQ:NRXP) Announce Signing of Definitive Agreement to Purchase Kadima Neuropsychiatry Institute; Foundational Acquisition for the HOPE Network of Interventional Psychiatry Clinics

May 12, 2025, 8:03 AM EDT - 10 months ago

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Report First Quarter 2025 Financial Results on May 15, 2025

May 6, 2025, 8:03 AM EDT - 10 months ago

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Investor Event at Mar-A-Lago Club on May 8, 2025

May 5, 2025, 8:03 AM EDT - 10 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Files Patent Application for NRX-100, its Proprietary, Preservative Free Formulation of IV Ketamine

Apr 30, 2025, 8:46 AM EDT - 10 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces FDA Award of Filing Fee Waiver for Upcoming NRX-100 (preservative free ketamine) New Drug Application to Treat Patients with Suicidal Depression

Apr 21, 2025, 8:01 AM EDT - 11 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics™, Inc.to Participate in an H.C. Wainwright @ Home Fireside Discussion on Tuesday, April 22, 2025

Apr 3, 2025, 8:03 AM EDT - 11 months ago

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Signing of a Term Sheet for Strategic Investment from a Global Medical Device Manufacturer into HOPE

Mar 31, 2025, 8:02 AM EDT - 11 months ago

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Definitive Purchase Agreement with Dura Medical; Initial Acquisition for Planned International Network of Interventional Psychiatry Clinics

Mar 24, 2025, 8:02 AM EDT - 1 year ago

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Signing of Binding Letter of Intent with Neurospa TMS Holdings, LLC for Expansion of its Planned International Network of Interventional Psychiatry Clinics

Mar 17, 2025, 10:50 AM EDT - 1 year ago

NRx Pharmaceuticals, Inc. (NRXP) Q4 2024 Earnings Call Transcript

Mar 17, 2025, 8:02 AM EDT - 1 year ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Outcomes Feb. 25 at 11:21 AM

$NRXP

0 · Reply

the_franz Feb. 25 at 8:16 AM

1 · Reply

JavittMD Feb. 24 at 10:35 PM

4 · Reply

BlazingStocks Feb. 24 at 8:34 PM

0 · Reply

jonny80s Feb. 24 at 8:02 PM

$NRXP sometimes I wonder if Anson was selling call options all of 2025 knowing full well that none of Javitt’s “wishful thinking” projections had any chance in hell of materializing.

0 · Reply

IChiGOdoranZ Feb. 24 at 7:29 PM

$NRXP New to The Street and Wall Street New York Magazine Launch Weekly Executive Publication with Integrated NewsOut Video Press Distribution

0 · Reply

Stockprofiler Feb. 24 at 6:43 PM

0 · Reply

DonDon531 Feb. 24 at 5:13 PM

$NRXP looking good!!!

0 · Reply

fuctonfauci Feb. 24 at 4:31 PM

$NRXP How many years does the FDA take to provide written feedback for a Type C meeting with NRx?

2 · Reply

Stockfit1 Feb. 24 at 4:21 PM

@ItTakesItAll Did you add $NRXP back in January

0 · Reply

Tyler444 Feb. 24 at 4:15 PM

$NRXP anybody seeing this why is this up today?

1 · Reply

BlazingStocks Feb. 24 at 2:19 PM

$NRXP News January 16, 2026 NRx Pharmaceuticals (Nasdaq:NRXP) Announces 2025 Annual Meeting Date and Record Date https://finance.yahoo.com/news/nrx-pharmaceuticals-nasdaq-nrxp-announces-120300570.html

0 · Reply

IChiGOdoranZ Feb. 24 at 2:12 PM

$NRXP News : Announces Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 (ketamine) Following Type C FDA Meeting https://www.reddit.com/r/Pennystocksv2/comments/1rdh9gy/nrx_pharmaceuticals_nasdaqnrxp_announces_path_to/

0 · Reply

Outcomes Feb. 24 at 1:29 PM

$NRXP ....Save the children. 🙏 🙏 🙏 https://abc7chicago.com/post/ketamine-treatment-offers-hope-teenagers-severe-depression-teen-shares-story-anxiety-eating-disorder-ptsd/18640152/

1 · Reply

SoloBueno Feb. 24 at 12:44 PM

$NRXP Red Flags: a. review of compensation is conducted every three years; b. within the past five (5) years, the frequency and rationale for changes in auditors; and c. utilization of a virtual office. The aforementioned factors, namely a., b., and c., are indicative of a pronounced lack of accountability. When considered in conjunction with the 1099 compensation structure, these elements collectively suggest a heightened risk of organizational instability and potential malfeasa…..you got it Bottom line: 3yr pay - avoids annual performance scrutiny; Auditor swaps - leads to delays in filings / opinion shopping, amongst other things ( as experienced) ; Virtual - avoids physical, in-person interactions with shareholders. Definition of atypical publicly traded company? No! This aligns with NDA , filing, pain data, tax free dividends and board member departures. Good luck.

1 · Reply

fuctonfauci Feb. 24 at 12:33 PM

$NRXP When does management plan to release something useful again? Asking for a long-term investor.

0 · Reply

ddimlich Feb. 23 at 11:28 PM

$NRXP here is the first link https://ir.nrxpharma.com/sec-filings/sec-filing/def-14a/0001437749-26-005119

0 · Reply

ddimlich Feb. 23 at 11:26 PM

$NRXP oops that was 8k here is the ARS https://ir.nrxpharma.com/sec-filings/sec-filing/424b5/0001437749-26-004244

1 · Reply

ddimlich Feb. 23 at 11:25 PM

$NRXP ok they also just filed the annual report https://ir.nrxpharma.com/sec-filings/sec-filing/8-k/0001437749-26-004246

0 · Reply

ddimlich Feb. 23 at 10:21 PM

$NRXP just filed a Form DEF 14A which has a lot of data. Interesting it talks about 2024 salary and 2023 salary for executive compensation but nothing about 2025 at least in my quick glance. But it’s 30 plus pages with some new data elements to be discussed at the annual meeting.

1 · Reply

BlazingStocks Feb. 23 at 8:42 PM

$NRXP - NRx together with Osmind, Inc. conducted an in-person meeting attended by leadership of the FDA Division of Psychiatry Products and leadership of the FDA Center for Drug Evaluation and Research (CDER) https://finance.yahoo.com/news/nrx-pharmaceuticals-nasdaq-nrxp-announces-120000758.html

1 · Reply

jonny80s Feb. 23 at 6:18 PM

$NRXP so now that Javitt has forged a path forward with the FDA: why doesn’t he share that path forward with his shareholders? Shareholders are tired of the promises and wishful thinking that never amount to progress. I’m looking forward to th 30 month realtime stability tests that will be completed mid March. And maybe Javitt will relate the results from th 24 month tests that he said he would release in the quarterly, but then never did. @JavittMD

1 · Reply

Market Cap	56.10M
Revenue (ttm)	0.00
Net Income (ttm)	-25.13M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	14.72
Profit Margin	0.00%
Debt to Equity Ratio	-0.39

Volume	951,100
Avg Vol	1,052,858
Day's Range	N/A - N/A
Shares Out	31.87M
Stochastic %K	88%
Beta	1.92
Analysts	Sell
Price Target	$36.75